Low-dose IL-2 after heart attack to study tissue-resident regulatory T cells
Official title: Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells
Run by Cambridge University Hospitals NHS Foundation Trust · NCT07610538 · Data updated 2026-11-12
Researchers are testing whether low-dose interleukin-2 given after a myocardial infarction can boost tissue-resident regulatory T cells to support heart repair.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | Cambridge University Hospitals NHS Foundation Trust Academic / other |
| Locations | 2 sites (Cambridge, Cambridgeshire and 1 other locations) |
| Status | Recruiting |
| Started | March 31, 2026 |
| Main results expected | November 1, 2028 |
| Study ends | December 1, 2028 |
| Registry record updated | May 28, 2026 |
| Trial ID | NCT07610538 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults undergoing CABG who meet the inclusion criteria and do not have the exclusion criteria, particularly without active infection, autoimmune disease, or significant hepatic/kidney disease.
✕Probably not a fit
Patients with active infection, autoimmune disease, severe organ dysfunction, or those allergic to aldesleukin may not benefit from this treatment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial investigates the effect of systemic low-dose Aldesleukin (IL-2) on tissue-resident regulatory T cells in patients undergoing CABG after myocardial infarction. Using single-cell and single-nucleus RNA sequencing, the study compares Treg signatures in heart-adjacent tissues to peripheral blood Tregs to see if ld-IL-2 promotes an anti-inflammatory, tissue-repairing phenotype. Participants receive ld-IL-2 alongside standard care, with assessments focused on tissue vasculature and cardiac tissues and their relationship to circulating immune cells. The investigation builds on prior work showing ld-IL-2 effects in blood, aiming to determine whether similar tissue-level effects occur and whether this could translate to improved clinical outcomes such as reduced heart failure.
Why it matters
Potential benefit: If successful, ld-IL-2 could promote tissue repair and reduce heart failure risk after myocardial injury by modulating tissue-resident Tregs.
How similar studies have gone: Prior trials explored ld-IL-2 effects in circulating Tregs; this study extends the question to tissue-resident Tregs, with mixed novelty and some supporting evidence in blood-based studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged over 18 years old * Undergoing CABG surgery Exclusion Criteria: * Critical left main stem coronary disease * Severe valvular disease (for example 'severe' aortic stenosis as classified on echocardiogram report) * Haemodynamic instability caused by arrhythmia requiring cardioversion in the current admission * Non-sustained ventricular tachycardia of \>10 beats in the last 48 hours * Autoimmune disease * Any regular immunosuppressive treatment \[Inhaled or topical steroids are permissible\] * Known active hepatic disease or alanine aminotransferase (ALT) \> 3xULN * Severe chronic kidney disease (defined as eGFR \< 30 ml/min/1.73m2) * Allergy or intolerance to aldesleukin * Signs and symptoms of active infection * History of human immunodeficiency virus (HIV), hepatitis B or C * Current malignancy requiring active treatment * Vaccine within 4 weeks prior to screening * Women of child-bearing potential and pregnancy (women must be either postmenopausal (defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile (e.g. age appropriate (\>55 years old), history of vasomotor symptoms) or having documented hysterectomy and/or bilateral oophorectomy) * Women who are breast-feeding * Clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study
Where it's running
-
Royal Papworth Hospital NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom Recruiting -
Addenbrooke's Hospital
Cambridge, Cambridgeshire, United Kingdom Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bypass surgery versus stents for people with weak heart pumping and blockages in multiple coronary arteries
This trial tests whether bypass surgery (CABG) or stents (PCI) lead to better survival, fewer major heart problems, and improved quality of life for adults with reduced left ventricular function (LVEF ≤40%) and multivessel coronary disease.
-
Virtual reality or eye mask during dressing after coronary artery bypass
This study tests whether wearing a virtual reality headset or an eye mask during dressing after coronary artery bypass surgery can reduce pain, anxiety, and stress-related vital sign changes in adults recovering from CABG.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease
This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.